Although, blocking IGF1R signaling by pharmaceutical inhibitors or blocking antibodies failed to show significant clinical benefit in pancreatic cancer [45, 57], a recent study by Camblin et al. showed that activation of IGF1R and ErbB3 reduced pancreatic cancer cells’ sensitivity to gemcitabine and paclitaxel and activation of ErbB receptor signaling confers resistance to IGF1R inhibition [45] in pancreatic cancer. Here, IGF1R is linked to familial pancreatic carcinoma.